Product vision |
|
MoA |
|
Key features |
- M5717: Long half-life and comparable activity across all stages of the malaria parasite lifecycle; transmission-blocking activity in a Standard Membrane Feeding Assay, and activity against hepatic schizonts
- Pyronaridine: is a combination partner in Pyramax (since 2012 EMA positive scientific opinion under art. 58), fast acting and long duration
- Positive interaction demonstrated in pre-clinical model on killing rate and resistance protection
|
Challenges |
- Dose and cost of Goods
- Potential for resistance against M5717
|
Status |
- M5717: First-in-human study (blood-stage) volunteer infection study and (sporozoite) volunteer infection study completed
|
Next milestone |
- Initiate phase IIa combination study in patients with acute uncomplicated malaria
|
Previously |
- Discovery collaboration with the University of Dundee Drug Discovery Unit
- Names DDD107498; DDD498, MMV121
|
MMV Project Director |
|